EGFR and breast carcinoma: Encouragingly, our findings demonstrate a significant association between the drug response to gefitinib and erlotinib and a gained active SCRE ("Pair_92_SCRE61’, a super-enhancer cataloged in Reference (34)) in EGFR specific to basal breast cancer (Supplementary Figure S5).